Difference between revisions of "Vismodegib (Erivedge)"
m |
m |
||
| Line 1: | Line 1: | ||
| − | Also known as GDC-0449. '''FDA approved | + | Also known as GDC-0449. '''FDA approved '''. |
==General information== | ==General information== | ||
| Line 13: | Line 13: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.erivedge.com/patient/medication-guide.html Erivedge patient medication guide]<ref>[http://www.erivedge.com/patient/medication-guide.html Erivedge patient medication guide]</ref> | *[http://www.erivedge.com/patient/medication-guide.html Erivedge patient medication guide]<ref>[http://www.erivedge.com/patient/medication-guide.html Erivedge patient medication guide]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *1/30/2012: Initial FDA approval "for the treatment of adults with metastatic [[Basal cell and squamous cell skin cancer|basal cell carcinoma]], or with locally advanced [[Basal cell and squamous cell skin cancer|basal cell carcinoma]] that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation." | ||
| + | |||
| + | ==Also known as== | ||
| + | Hedgehog antagonist GDC-0449, GDC-0449, Erivedge | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Oral chemotherapy]] | ||
[[Category:Hedgehog pathway inhibitors]] | [[Category:Hedgehog pathway inhibitors]] | ||
Revision as of 20:16, 15 December 2014
Also known as GDC-0449. FDA approved .
General information
Class/mechanism: Hedgehog pathway inhibitor. Vismodegib binds to and inhibits the transmembrane protein Smoothened (SMO), which is part of the Hedgehog signal transduction pathway that is clinically relevant in diseases such as basal cell cancer.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 1/30/2012: Initial FDA approval "for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation."
Also known as
Hedgehog antagonist GDC-0449, GDC-0449, Erivedge